Integrated Treatment to Achieve Functional Recovery for First-Episode Psychosis

Table 2

Symptomatology (PANSS) and global functioning (GAF) of the study groups at baseline and at the end of treatment.

	Experimental; 𝑛=39	Control; 𝑛=34	Statistics^b
			Main effect for time	Main effect for group	Interaction of group and time
PANSS^a overall score, 𝑋(𝑠)
Baseline	86.9 (41.1)	78.8 (35.6)	𝑃<.001	—	𝑃<.01
Post treatment	40.2 (9.6)	52.7 (15.7)
Effect size	−1.1	−.7
PANSS positive^a, 𝑋(𝑠)
Baseline	19.2 (10.9)	17.0 (10.2)	𝑃<.001	—	—
Post treatment	8.5 (2.0)	10.4 (4.0)
Effect size	−1.0	−.6
PANSS negative^a, 𝑋(s)
Baseline	23.1 (11.5)	21.5 (10.1)	𝑃<.001	—	𝑃<.01
Post treatment	10.4 (3.9)	14.6 (6.3)
Effect size	−1.1	−.7
PANSS GPS^a, c, 𝑋(s)
Baseline	44.6 (20.6)	40.2 (17.0)	𝑃<.001	—	𝑃<.05
Post treatment	21.3 (4.6)	27.6 (8.1)
Effect size	−1.1	−.7
Level of global functionig^d (GAF), 𝑋(s)
Baseline	44.2 (6.8)	44.7 (6.9)	𝑃<.001	𝑃<.001	𝑃<.001
Post treatment	68.0 (9.3)	46.6 (10.2)
Effect size	3.5	.28

Notes: ^ahigher scores indicate more severe symptoms, ^banalysis of variance for repeated measures,
^cGPS: general psychopathology scale, ^dhigher scores indicate better global functioning.